These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17300908)

  • 1. The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Máthé A; Szabó D; Anderlik P; Rozgonyi F; Nagy K
    Diagn Microbiol Infect Dis; 2007 May; 58(1):105-10. PubMed ID: 17300908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo selection of imipenem-resistant Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-15 and plasmid-encoded DHA-1 cephalosporinase.
    Cuzon G; Naas T; Guibert M; Nordmann P
    Int J Antimicrob Agents; 2010 Mar; 35(3):265-8. PubMed ID: 20034767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.
    Cobo J; Morosini MI; Pintado V; Tato M; Samaranch N; Baquero F; Cantón R
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):319-22. PubMed ID: 17996417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases.
    Conejo MC; Hernández JR; Pascual A
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF; Zhou J; Qin JP
    Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
    Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
    [No Abstract]   [Full Text] [Related]  

  • 15. Bactericidal effect of beta-lactams and amikacin alone or in association against Klebsiella pneumoniae producing extended spectrum beta-lactamase.
    Roussel-Delvallez M; Sirot D; Berrouane Y; Goffart M; Gourde B; Wallet F; Courcol RJ
    J Antimicrob Chemother; 1995 Jul; 36(1):241-6. PubMed ID: 8537274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.
    Psichogiou M; Tassios PT; Avlamis A; Stefanou I; Kosmidis C; Platsouka E; Paniara O; Xanthaki A; Toutouza M; Daikos GL; Tzouvelekis LS
    J Antimicrob Chemother; 2008 Jan; 61(1):59-63. PubMed ID: 17999975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
    Paterson DL; Ko WC; Von Gottberg A; Mohapatra S; Casellas JM; Goossens H; Mulazimoglu L; Trenholme G; Klugman KP; Bonomo RA; Rice LB; Wagener MM; McCormack JG; Yu VL
    Clin Infect Dis; 2004 Jul; 39(1):31-7. PubMed ID: 15206050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae.
    Lin RD; Chin YP; Lee MH
    Phytother Res; 2005 Jul; 19(7):612-7. PubMed ID: 16161024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nosocomial liver abscess caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
    Lin JC; Siu LK; Fung CP; Yeh KM; Chang FY
    J Clin Microbiol; 2007 Jan; 45(1):266-9. PubMed ID: 17093025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sanfetrinem, the member of trinems--in vitro activity against Klebsiella pneumoniae producing ESBL].
    Wieczorek P; Sacha PT; Leszczyńska K; Jakoniuk P; Zalewska M
    Med Dosw Mikrobiol; 2006; 58(1):27-32. PubMed ID: 16871970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.